Form 4: Acrivon Therapeutics Insiders Report Routine Stock Transactions for Tax Purposes
Insider Transaction Report
Acrivon Therapeutics, Inc. insiders Peter Blume-Jensen and Kristina Masson filed a Form 4 detailing the withholding of shares to cover tax obligations upon the vesting of restricted stock units.
Summary
- Acrivon Therapeutics, Inc. (ACRV) filed a Form 4 reporting changes in beneficial ownership for President and CEO Peter Blume-Jensen and EVP Business Operations Kristina Masson.
- On May 21, 2025, 19,904 shares of Common Stock were disposed of by Peter Blume-Jensen at a price of $1.15 per share.
- This disposition was identified with transaction code 'F', indicating shares withheld by the Issuer to satisfy mandatory tax withholding requirements upon the vesting of restricted stock units.
- Following this transaction, Peter Blume-Jensen directly beneficially owns 2,206,111 shares of Common Stock.
- Kristina Masson indirectly beneficially owns 315,686 shares of Common Stock, which are held by her spouse, Peter Blume-Jensen; she disclaims beneficial ownership except to the extent of her pecuniary interest.
- Peter Blume-Jensen also indirectly beneficially owns 315,686 shares held by his spouse, Kristina Masson, disclaiming beneficial ownership except to the extent of his pecuniary interest.
Sentiment
Score: 5
Explanation: Neutral. This is a routine compliance filing for tax withholding upon RSU vesting, which is a common and expected event for executive compensation and does not inherently indicate positive or negative operational performance or strategic shifts.
Positives
- The transaction represents the vesting of restricted stock units, which is a positive event for the executives as it signifies the realization of compensation.
Negatives
- No direct negatives are indicated by this routine tax withholding transaction.
Risks
- The document itself, being a compliance filing for a routine transaction, does not introduce new specific risks to the company or its operations.
Future Outlook
N/A
Industry Context
N/A
Related Party Transactions
- The filing explicitly notes the spousal relationship between Peter Blume-Jensen and Kristina Masson, and their respective indirect beneficial ownership of each other's holdings, with disclaimers of beneficial ownership except to the extent of pecuniary interest.
Stakeholder Impact
- Minimal impact on shareholders as this is a routine tax-related transaction for executive compensation and does not reflect a discretionary sale or purchase of shares.
Key Dates
| Date | Description |
|---|---|
| 05/17/2025 | Date of Power of Attorney for Peter Blume-Jensen. |
| 05/21/2025 | Date of earliest transaction (shares withheld for tax upon RSU vesting). |
| 05/21/2025 | Date of Power of Attorney for Kristina Masson. |
| 05/23/2025 | Signature date of the Form 4 filing by attorneys-in-fact. |
Keywords
Acrivon Therapeutics, ACRV, Form 4, Insider Transaction, Stock Ownership, Restricted Stock Units, Tax Withholding, Beneficial Ownership, Peter Blume-Jensen, Kristina Masson
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.